Ascendis Pharma: Patients. Science. Passion.
Ascendis Pharma is a global biopharmaceutical company committed to making a meaningful difference in patients’ lives. Guided by our core values of Patients, Science, and Passion, we …
Ascendis Pharma U.S.: Patients. Science. Passion.
We apply our TransCon technology platform to build a leading, fully integrated biopharma company & make a meaningful difference for patients.
After 2 delays over 15 months, FDA approves Ascendis' Yorvipath
Aug 12, 2024 · After two delays, the FDA has signed off on Ascendis' Yorvipath, which is the first approved product for hypoparathyroidism in adults in the US.
Ascendis Pharma - LinkedIn
Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our …
Assessing Ascendis Pharma’s 2025 Valuation After Big Run and …
Dec 21, 2025 · If you are wondering whether Ascendis Pharma is still a smart buy after its big run, or if the market has already priced in the upside, this overview is designed to give you a clear, …
Rice Hall James & Associates LLC Trims Stock Holdings in Ascendis ...
4 days ago · Ascendis Pharma A/S comprises about 1.6% of Rice Hall James & Associates LLC's portfolio, making the stock its 14th biggest holding. Rice Hall James & Associates LLC owned …
Ascendis
Ascendis Health is a health and wellness company offering various consumer and medical products.
Ascendis Pharma and Novo Nordisk Sign Collaboration for
Nov 4, 2024 · - Collaboration leverages Ascendis’ proprietary TransCon™ technologies and Novo Nordisk’s expertise in cardiometabolic diseases - Once-monthly GLP-1...
Ascendis Pharma, Inc. - Pediatric Endocrine Society
About Us: Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided …
About Us - Ascendis Pharma
Ascendis Pharma was founded in 2007 based on the innovative TransCon technology platform. We are headquartered in Copenhagen, Denmark and are publicly traded, following an initial …